Positive Phase 1 Results for ImmunAbs' IM-101 Clinical Trial

ImmunAbs, a biotechnology firm based in Seoul, South Korea, has achieved milestone success by completing Phase 1 clinical trials for their new antibody therapeutic, IM-101. IM-101 is a humanized monoclonal antibody that strategically targets complement C5, a key player in the complement system known for its role in autoimmune diseases.

The clinical trial was a randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability, and initial efficacy of IM-101. Participants, who were healthy volunteers, were given varying single doses of either IM-101 or a placebo. The drug demonstrated excellent tolerability with no severe side effects or dose-limiting toxicity across all doses tested. All the trial's predetermined objectives were successfully achieved.

ImmunAbs' CEO, Dr. Dongjo Kim, expressed satisfaction with the results, highlighting that the study successfully verified IM-101's capability to bind with complement C5 in humans by measuring serum free C5 levels. Dr. Kim noted that these promising outcomes provide a strong basis for meeting the medical needs of patients who still suffer from symptoms despite existing treatments. The company is enthusiastic about exploring IM-101's potential in the upcoming Phase 2 trials.

Founded in 2017, ImmunAbs is dedicated to creating groundbreaking antibody therapies, with a particular focus on severe autoimmune diseases. Financed through equity capital and government funds, they are seeking further investments and collaborations to bring IM-101 closer to market availability.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!